Project Title

A study comparing Abelacimab to Dalteparin in the treatment of gastrointestinal/genitourinary cancer and associated VTE (MAGNOLIA)

Official Title

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of Abelacimab vs. Dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with GI/GU associated VTE.

Project Summary

Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by high incidence of Venous thromboembolism (VTE) recurrence and high risk for bleeding. Patients with intact GI and GU cancer have increased bleeding risk with oral direct anticoagulants (DOACs), Guidelines advice caution with those DOACs or state preference for low molecular weight heparin (LMWH) in this population. The ANT-008 study will compare treatment with abelacimab monthly administration to LMWH daily subcutaneous (sc) administration over 6-month treatment. The study outcomes include VTE recurrence, bleeding event and treatment discontinuation at 6 months

Blood Disorder

  • Venous thromboembolism
  • Deep venous thromboembolism
  • Pulmonary embolism

Patient Recruitment Details

Patient recruitment status: closed

Number of patients (Globally)